Research advances in immune checkpoint inhibitor-related cholangitis

VernacularTitle:免疫检查点抑制剂相关胆管炎的研究进展
Author: Yucheng HOU ¹ ; Hongqiang ZHAO ¹ ; Caoer DONG ¹ ; Guangdong WU ¹ ; Xuan TONG ¹ ; Ang LI ¹ ; Qian LU ¹ ; Hong CHEN ¹ ; Rui TANG ¹
Author Information

1. Hepatobiliary and Pancreatic Center, Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
Publication Type:Review
Keywords: Immune Checkpoint Inhibitors; Cholangitis; Programmed Death-1
From: Journal of Clinical Hepatology 2023;39(2):463-468
CountryChina
Language:Chinese
Abstract: Immune checkpoint inhibitors (ICIs) have ushered in a new era of tumor treatment; however, immunotherapy-related adverse events are critical issues that restrict the clinical application of ICIs and have attracted wide attention. The liver is one of the target organs that is easily affected. With the progress in research, scholars have found that besides hepatocytes, intrahepatic and extrahepatic bile ducts can also be attacked by the immune system, leading to the disease known as immune-related cholangitis. This article reviews the research advances in ICI-related cholangitis by summarizing related articles, in order to preliminarily reveal its clinical, pathological, and imaging features and provide clues for early identification, standard treatment, and subsequent research.